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Summary 
Clarifying the preclinical profiles of drug candidates is essential for estimating their 
clinical performance. However, the applicability of preclinical research to clinical profiles varies a 
great deal depending on the availability of suitable experimental models. In this study, I attempt to 
assess two drug candidates for which the clinical potential was difficult to estimate from the 
preclinical research because of species specificity and the lack of appropriate models. 
Firstly, the effects of interleukin 6 (IL-6) signal blocking agents are evaluated in 
 disease mice by administering anti-IL-6 receptor (IL-6R) 
monoclonal antibody (mAb)
hyperplasia, plasmacytosis, fever, anemia, and hypergammaglobulinemia with an abnormal 
augmentation of IL-6, and blocking the IL-6 function by using a mAb to human IL-6R results in 
beneficial effects in the patients. The H-2Ld human IL-6 transgenic mice (IL-6 tgm) develop various 
disorders associated with dysregulated IL-6 overproduction, and most of these disorders are identical 
-
prepared a rat mAb to mouse IL-6R that would block the IL-6 signal in IL-6 tgm, which, when 
administered, almost completely prevented these symptoms and prolonged the life of the mice 
without severe adverse events. Thus, the clinically proven efficacy of the IL-6R mAb against 
preclinical experiment. 
Next, the therapeutic potential of a recently identified drug candidate to treat Hepatitis C 
virus (HCV) is assessed in preclinical examinations. HCV affects approximately 170 million people 
worldwide and can result in a persistent infection that leads to chronic hepatitis, cirrhosis, and 
hepatocellular carcinoma. Unfortunately, the interferon (IFN)-based current standard therapy has 
limited efficacy and significant side effects. Although combinations of direct-acting antiviral agents 
(DAAs) without IFN have been tested for clinical use as novel anti-HCV therapies, emerging data 
suggest that DAAs might select for resistance, which can become a primary cause of treatment 
failure in clinical studies. Additionally, differences in HCV genotypes can result in certain DAAs 
having reduced antiviral activity. Therefore, the development of additional antiviral agents with 
diverse resistance profiles and efficacy against a wide spectrum of HCV genotypes is necessary. To 
this end, I have identified a novel class of serine palmitoyltransferase (SPT) inhibitors that inhibited 
HCV replication by disrupting the host cell lipid rafts, which act as a scaffold for HCV replication. 
This unique mechanism of host enzyme-targeted viral inhibition is hypothesized to have potential for 
its high barrier to resistance and for its antiviral activity across different HCV genotypes.  
Preclinical research of HCV replication has been limited by the lack of appropriate 
infection models. One model that has been reported as being possibly infected with HCV was 
produced by transplanting human primary hepatocytes into severe combined immunodeficient mice 
carrying the urokinase plasminogen activator transgene controlled by an albumin promoter. Here, I 
use these mice to assess the therapeutic potential of a SPT inhibitor, NA808, in clinical practice by 
investigating the efficacy across HCV genotypes, its synergistic effects with other antiviral agents, 
and the potential development of resistance. 
These humanized liver chimeric mice infected with HCV genotypes 1a, 1b, 2a, 3a, and 4a 
could support long-term HCV infections at clinically relevant titers. Administration of NA808 
results in approximately 1- to 3-log reductions in each genotype-infected group, which indicates that 
NA808 has a robust antiviral effect across HCV genotypes. In addition, NA808 has synergistic 
effects when combined with pegylated IFN (PEG-IFN), NS3/4A protease inhibitor, or NS5B 
polymerase inhibitors, regardless of the targeted enzyme. When a full-genome sequence analysis of 
HCV in NA808-treated chimeric mice was performed to evaluate the potential for resistance to 
develop, the viral sequences from NA808-treated mice were identical to those from untreated mice. 
This high barrier to resistance is also confirmed by an in vitro study using HCV sub-genomic 
replicon cells. 
Thus, NA808 mediates potent anti-HCV activity in a variety of genotypes with an 
apparently high barrier to resistance and has synergistic effects with other anti-HCV agents. These 
findings suggest that NA808 has potential as a novel host-targeted drug in the treatment of HCV 
infection. 
In conclusion, the results in the Castleman s disease model treated with anti-IL-6R mAb 
suggest that preclinical assessment might be capable of predicting the clinical performance, when 
using appropriate models with clinical relevance. In HCV-infected humanized liver chimeric mice, 
viral replication occurred in human hepatocytes, and long-term infection could be supported at a 
clinically relevant titer; hence, these mice are considered a suitable model with clinical relevance for 
evaluating anti-HCV drug candidates. Therefore, beneficial profiles of NA808 as an anti-HCV drug 
in HCV-infected humanized liver chimeric mice were able to reflect the drug s clinical potential and 
support the development of NA808 as a treatment for HCV infection or for use in combination with 
PEG-IFN alfa-2a or HCV polymerase or with protease inhibitors. 
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Introduction
Clarifying the preclinical profiles of drug candidates is essential for estimating their 
clinical performance. However, the applicability of preclinical research to clinical profiles varies a 
great deal depending on the availability of suitable experimental models. In this study, I attempt to 
assess two drug candidates whose clinical potential had been difficult to estimate from the 
preclinical research because of species specificity and the lack of appropriate models. 
Firstly, to confirm the beneficial effects of IL-6 signal-blocking agents in patients with 
se, their effects are evaluated mice by 
administering anti-IL-6 receptor (IL-6R) monoclonal antibody (mAb). IL-6 is a pleiotropic cytokine 
that acts on a wide variety of tissues and causes growth promotion, growth inhibition, differentiation, 
and induction of specific gene expression according to the type of target cells [2]. In addition to 
these multiple functions of IL-6, various types of biological activity could be significantly modulated 
by the existence of a soluble receptor that elicits agonistic signals through gp130 by forming a 
complex with IL-6. So, an abnormal augmentation of IL-6 has been suggested to be involved in the 
pathogenesis of certain disorders [6, 37]. associated with lymph 
node hyperplasia, plasmacytosis, fever, anemia, and hypergammaglobulinemia that occur when IL-6 
is abnormally augmented. Therefore, blocking the IL-6 signal transduction could provide a 
therapeutic strategy for Several researchers have attempted to block the IL-6 
function using a mAb against IL-6 or IL-6R mAb to neutralize the IL-6 function and beneficial 
effects on patients with disease have been reported [5, 23]. 
I have established H-2Ld human IL-6 transgenic mice (IL-6 tgm) which develop various 
disorders, including massive IgG1 plasmacytosis, mesangial proliferative glomerulonephritis, 
thrombocytosis, leukocytosis, anemia, and muscle atrophy, and which, upon aging, develop marked 
increases in serum IL-6 levels and die early from renal failure [15]. Most of these disorders are 
 disease, so IL-6 tgm could be useful 
model to examine its pathological features and evaluate the therapeutic efficacy of drug candidates. I 
also prepared a rat anti-mouse IL-6R mAb to block the IL-6 signal in these IL-6 tgm, since the 
anti-IL-6R mAb used in clinic is human specific. This rat anti-mouse IL-6R mAb was selected based 
on the in vivo antagonism it showed to IL- y in two experimental models. 
Next, the therapeutic potential of a recently identified anti-Hepatitis C virus (HCV) drug 
candidate is assessed in preclinical examinations. HCV is a major cause of morbidity, affecting 
approximately 170 million people worldwide [35]. In many cases, HCV results in a persistent 
infection that evades the host immune response, leading to chronic liver disease, chronic hepatitis, 
cirrhosis, and hepatocellular carcinoma [3]. The current therapy for chronic hepatitis C is a 
combination of weekly injections of pegylated interferon alfa-2a (PEG-IFN) and twice-daily oral 
doses of ribavirin (RBV). Unfortunately, this combination therapy has limited efficacy and 
significant side effects [7, 20]. Although HCV NS3/4A protease inhibitors, telaprevir and boceprevir, 
have been approved to treat chronic HCV infection, these compounds must be combined with the 
current standard of care to be efficacious, and there are some infected individuals, including 
IFN-intolerant patients, that they cannot cure [11, 17, 28]. Therefore, antiviral combinations that can 
achieve a superior sustained virologic response without the use of IFN or RBV are needed. IFN-free 
combinations of direct-acting antiviral agents (DAAs) have been tested for clinical use as novel 
anti-HCV therapies [8, 26, 38]. Emerging data suggest that DAAs, including NS3/4 serine protease 
inhibitors, NS5B RNA-dependent RNA polymerase inhibitors, and NS5A inhibitors, can achieve 
significant antiviral activity when used in combination, but might select for resistance, which can 
become a primary cause of treatment failure in clinical studies, especially in difficult-to-treat HCV 
genotypes [26, 38]. Additionally, differences in HCV genotypes can result in reduced antiviral 
activity by certain DAAs and DAA combinations [9]. Therefore, developing additional antiviral 
agents with diverse resistance profiles and efficacy against a wide spectrum of HCV genotypes is 
necessary. Major efforts are underway to identify novel inhibitors and DAA combinations with a 
high barrier to resistance for the treatment of HCV infection. 
I have identified a novel class of serine palmitoyltransferase (SPT) inhibitors derived from 
fungal metabolites that exhibited HCV replication-inhibiting activity [27]. HCV replication occurs 
on host cell lipid rafts that form a scaffold for the HCV replication complex. Sphingolipids, the 
downstream products of SPT action, are essential components of lipid rafts associated with HCV 
nonstructural proteins on this microdomain. By preventing the de novo synthesis of sphingolipids, an 
SPT inhibitor disrupts the HCV replication complex and thereby inhibits HCV replication. This 
unique mechanism of host enzyme-targeted viral inhibition was hypothesized as having a high 
barrier to resistance and antiviral activity across different HCV genotypes. I identified a novel 
compound, NA808, which is a derivative of the previously described compound NA255 with further 
improved properties, including improved replicon potency from a 50% effective concentration of 2 
nM for NA255 to a 50% effective concentration of 0.84 nM for NA808 [27]. 
Preclinical research of HCV replication has been limited by the lack of appropriate 
infection models. The only animal species readily infected with HCV has been the chimpanzee, 
which is difficult to use because of critical ethical problems, the necessity of labor-intensive work, 
and high cost. One model that has been reported as being possibly infected with HCV was produced 
by transplanting human primary hepatocytes into severe combined immunodeficient (SCID) mice 
carrying the urokinase plasminogen activator transgene controlled by an albumin promoter [21]. In 
these mice, HCV replication occurs in reconstituted human hepatocytes at a clinically relevant titer 
[14]. Therefore, it is considered that this humanized liver chimeric mouse is suitable for evaluating 
the anti-HCV activity of NA808. In this examination, I attempt to assess the effectiveness of NA808 
alone and in combination with DAAs in humanized liver chimeric mice infected with HCV 
genotypes 1a, 1b, 2a, 3a, and 4a to evaluate the therapeutic potential of NA808 as a novel 
host-targeted HCV inhibitor, including efficacy across HCV genotypes, the potential development of 
resistance, and synergistic effects with other antiviral agents. 
Chapter 1: 
The effects of an anti-IL-6R antibody on human Castleman s disease-like 
symptoms in IL-6 transgenic mice 
1. Background and Aims 
fever, anemia, and hypergammaglobulinemia occurring when IL-6 is abnormally augmented [37]. 
Administering a mAb against IL-6 or IL-6R to neutralize the IL-6 function results in beneficial 
effects in patients with  [5, 23]. 
The IL-6 tgm that I established develop various disorders, including massive IgG1 
plasmacytosis, mesangial proliferative glomerulonephritis, thrombocytosis, leukocytosis, anemia, 
and muscle atrophy with dysregulated IL-6 overproduction. Most of these disorders are identical 
-6 tgm could be useful as a model for 
[15]. 
In Chapter 1, I describe the effects of IL-6 signal-blocking agents in IL-6 tgm to confirm 
the benefits in patients with Castleman s disease, and I estimate whether preclinical evaluation using 
an animal model that has been artificially accommodated to human disease can predict the clinical 
performance of a drug. To block the IL-6 signal transduction in mice, I prepared a rat anti-mouse 
IL-6R (mIL-6R) mAb with potent neutralizing activity of the IL-6 signal, since the anti-IL-6R mAb 
used in clinic is specific to humans. The rat anti-mIL-6R mAb was selected because it showed in 
vivo antagonism to IL- y in two experimental models. 
2.  Materials and Methods
Preparation of rat anti-mIL-6R mAbs 
Rat anti-mIL-6R mAbs (MR3-2, MR17-2, MR16-1, and MR44-10) were prepared as 
described previously [32], the isotypes of these antibodies were IgG2a (MR3-2 and MR17-1), IgG1 
(MR16-1), and IgG2b (MR44-10). Hybridomas recognizing mIL-6R were injected intraperitoneally 
into pristan-pretreated BALB/c nu/nu mice (Nippon Clea, Tokyo, Japan) to produce ascites. Rat 
anti-mIL-6R mAbs were purified from the ascites fluids with a protein G column (Oncogene Science 
Inc., Uniondale, NY, USA). 
Evaluate in vivo neutralizing activity of anti-mIL-6R mAbs 
The in vivo neutralizing activity of anti-mIL-6R mAbs against the effects of IL-6 was 
confirmed as follows.  
IL-6-dependent cell growth in C.B-17scid mice with human IL-6 transgene (IL-6 SCID): A 
mouse-IL-6 dependent cell line, MH60.BSF2 (MH60), was inoculated subcutaneously (1 106
cells/mouse) into the left flank of IL-6 SCID mice [15]. One day after transplantation, the mice were 
injected subcutaneously with a single 0.5 mg/body dose of anti-mIL-6R mAb or control rat IgG 
(Cappel, Durham, NC, USA) followed by doses of 0.1 mg/body twice weekly from 4 to 29 days 
after transplantation. Each group consisted of four mice. The tumor length and width were measured 
to calculate tumor volume by the following formula: 
tumor volume (mm3)=length (mm) width (mm)2/2 
Production of antigen specific antibody: Male C3H/HeJ mice (Nippon Clea, Tokyo, Japan) 
were injected with 0.1 mg of dinitrophenol-conjugated keyhole limpet hemocyanin (DNP-KLH) 
intravenously, and implanted in the back with Alzet micro-osmotic pumps (model 1007D: Alzet 
Corp., Palo Alto, CA, USA) loaded with recombinant human IL-6 (hIL-6) to deliver 6 g of hIL-6 
per day. These mice were injected with an anti-mIL-6R mAb or control rat IgG subcutaneously 1 day 
after immunization, and serum anti-DNP specific antibody was detected by ELISA 7 days after 
immunization using DNP-BSA and alkaline phosphatase conjugated goat anti-mouse IgG (ZYMED 
Lab., South San Francisco, CA, USA). The serum from C3H/HeJ mice hyper-immunized with 
DNP-KLH was used as a standard. 
Evaluating the effect of anti-IL-6R mAb in IL-6 tgm 
Male C57BL/6J hIL-6 tgm carrying hIL-6 cDNA fused with the H-2Ld promoter [15] were 
used. These mice were maintained under specific-pathogen free conditions and fed standard 
laboratory chow (CE-2. Nippon Clea, Tokyo, Japan) ad libitum. These mice were first injected with 
a single dose of 2 mg/body of MR16-1 or an isotype-matched control rat IgG1 antibody (KH5) 
intravenously at 4 weeks of age to induce tolerance to rat IgG in the mice, then subcutaneously with 
0.1 mg/body twice weekly from 5 to 17 weeks of age. Antibodies against anti-rat IgG were not 
detected in sera during the course of the study. From mice under anesthesia, peripheral blood 
samples were collected from the retro-orbital sinus at 4, 8, 12, and 18 weeks of age; blood for serum 
samples was collected from the inferior vena at 18 weeks of age. Left femur, kidney, spleen, 
mesenteric lymph node, liver, lung, and heart were removed and fixed with 20% neutral buffered 
formalin for histological examination. As control, normal littermate mice were used. Each group 
consisted of 5 to 7 mice. 
hIL-6-specific ELISA 
The serum concentration of hIL-6 was determined by hIL-6-specific ELISA as described 
in a previous report [21]. 
Mouse IgG1-specific ELISA 
ELISA was performed utilizing affinity-purified goat anti-mouse IgG1 and alkaline 
phosphatase conjugated affinity-purified rabbit anti-mouse IgG1 antibodies. Myeloma protein 
(mouse monoclonal IgG1) was used as a standard. All reagents were purchased from ZYMED 
Laboratories (South San Francisco, CA, USA). 
Hematological evaluations of peripheral blood 
Automated analysis was performed on a micro-cell counter (Sysmex® F-800, Toa Medical 
Electronics, Kobe, Japan). The analysis included: white blood cell (WBC), red blood cell (RBC), 
platelet counts, and hemoglobin levels. 
Measurement of blood chemical parameters 
Serum glucose (Glu), triglyceride (TG), total protein (TP), alkaline phosphatase (ALP), 
albumin (Alb), blood urea nitrogen (BUN), calcium (Ca), creatinine (Cre), glutamic-oxaloacetic 
transaminase (GOT) and glutamic-pyruvic transaminase (GPT) were measured using a COBAS 
FARA II automatic analyzer (Roche, Basel, Switzerland). 
Statistical analysis 
Statistical analysis of the data was performed by SPSS using the -test.
3.  Results 
In vivo neutralizing activity of anti-IL-6R mAbs 
To validate the in vivo inhibitory effect of anti-mIL-6R mAb upon IL-6 activity, one of 
four mAbs were each injected into MH60-bearing IL-6 SCID mice or C3H/HeJ mice immunized 
with DNP-KLH. The hIL-6 transgene accelerated the IL-6-dependent cell growth of MH60 (Fig. 
1-1), but treatment with each of the four anti-mIL-6R mAbs inhibited it. After transplantation into 
SCID mice without the IL-6 transgene, the tumor nodules became palpable at 12.00 3.6 (mean
SD) days. After transplantation into IL-6 transgenic SCID mice, individually treated with either 
control rat IgG, MR3-2, MR17-2, MR16-1, and MR44-10, palpable tumor nodules were observed at 
7.00 1.6, 11.75 2.1, 10.25 2.5, 15.25 2.5, and 13.75 3.5 days, respectively. There were 
significant differences (P<0.01) between each anti-mIL-6R mAb-treated group and the control rat 
IgG-treated group. In C3H/HeJ mice immunized with DNP-KLH, the suppressive effect of each 
anti-mIL-6R mAb on exogenous IL-6-enhanced anti-DNP IgG production was observed (Fig. 1-2). 
In particular, MR16-1 blocked the effect of hIL-6 in a dose-dependent manner. Because MR16-1 
antagonized the IL-6 activity most strongly in both in vivo experimental models, it was selected for 
further examination. 
Effect of MR16-1 on IgG1 plasmacytosis in IL-6 tgm 
In KH5-treated IL-6 tgm, serum IgG1 levels increased markedly with aging, and the 
concentration amounted to over 100-fold more than that of normal littermates (Fig. 1-3a). 
Morphological examination revealed splenomegaly and an enlargement of the lymph nodes, with a 
large number of plasma cells (Fig. 1-4). Furthermore, plasma cell infiltration was abundant in liver 
and kidney. These mice also exhibited remarkable increases in serum hIL-6 concentration with aging 
(Fig. 1-3b). Treatment with MR16-1 completely prevented the increase in serum IgG1 levels and the 
development of splenomegaly; the average weight of spleens was 0.10 0.015 g (mean SD) 
compared to those of the KH5-treated group (0.93 0.28 g) and the appearance of the spleens was 
almost normal upon histological observation at the end of the experiment (Fig. 1-4b). The 
concentration of serum hIL-6 was as high as 200 pg/ml at the beginning of treatment, and the levels 
remained constant during the course of the study. 
Suppression by MR16-1 of hematological abnormalities in IL-6 tgm 
The KH5-treated IL-6 tgm had marked decreases in RBC counts and hemoglobin levels, 
and anemia became severe with aging (Fig. 1-5). The platelet count was markedly increased by 10 
weeks of age compared with normal littermates, but subsequently underwent a dramatic decrease. In 
contrast, in IL-6 tgm treated with MR16-1, both anemia and thrombocytosis were mild and the RBC 
count and hemoglobin levels remained almost constant during the course of the study. 
Suppression by MR16-1 of the abnormalities in blood chemical parameters in IL-6 tgm 
The serum levels of TG, Glu, ALP, and Alb significantly decreased, and the serum TP 
levels increased in KH5-treated IL-6 tgm (Table 1-1). These morbid phenomena were normalized by 
the treatment with MR16-1. There were no significant differences in GOT, GPT, BUN, Ca, or Cre 
between the MR16-1-treated and KH5-treated groups. 
4.  Discussion 
In this examination, four anti-mouse IL-6R mAbs that neutralize the biological activity of 
IL-6 in vivo were established. In particular, MR16-1 has the strongest activity and may effectively 
suppress endogenous IL-6 activity, because the levels of IL-6-dependent tumor growth or 
antigen-specific antibody production in mice treated with MR16-1 were lower than those in mice 
without the IL-6 transgene or an IL-6 infusion (Figs 1-1 and 1-2). When MR16-1 is administered to 
IL-6 tgm, various disorders associated with IL-6 overexpression are completely prevented. These 
observations demonstrate that MR16-1 is a potent inhibitor against the biological activity of IL-6 in 
vivo and clearly confirm a significant role of IL-6 in the pathogeneses of a variety of disorders. 
The critical role of IL-  been reported [37]; that is, there is a 
strong correlation between serum IL-6 level and clinical abnormalities. In a patient with a solitary 
hyperplastic lymph node, a decrease in serum IL-6 level after surgical removal of the affected lymph 
node resulted in clinical improvement. In the present data, IL-6 tgm exhibit a variety of disorders, 
such as multiple plasmacytosis, hypergammaglobulinemia, anemia, lymphadenopathy, splenomegaly, 
and hypoalbuminemia. Furthermore, the expression of C-reactive protein and fibrinogen is reported 
as accelerated in IL-6 tgm [30]. These  the 
severity is closely correlated with serum IL-6 level (Fig. 1-3b). Therefore, IL-6 tgm could be 
regarded as a 
This examination indicated that treatment with anti-IL-6R mAb could block IL-6-mediated 
responses in vivo and completely eliminate various disorders in IL-6 tgm that are identical to those in 
Castleman s disease, including inflammatory, immune, hematopoietic, and metabolic abnormalities. 
On the other hand, anti-IL-6R mAb showed no severe adverse effects, even when injected into 
non-transgenic littermate mice. These findings are consistent with the previous report by Nishimoto 
et al. indicating that administering anti-human IL-6R antibody improves various symptoms, such as 
anemia, hypoalbuminemia, hypergammaglobulinemia, and lymphadenopathy, and with the fact that 
treatment is well tolerated in Castleman s disease patients [23]. Thus, the clinically proved efficacy 
of IL-  These 
results suggest that preclinical assessment using appropriate models that are clinically relevant might 
be capable of predicting clinical performance. 
Figure 1-1. Tumor volume in MH60-bearing SCID IL-6 mice treated with anti-mIL-6R mAbs 
at 16 days after transplantation.
Cells (1 106) were transplanted into the left flank of mice (n=4). Tumor volume was calculated as 
described in Materials and Methods. Data are presented as mean ( SD). 
Figure 1-2. Anti-DNP antibodies in immunized C3H/HeJ mice. 
Specific antibodies in sera were determined at 7 days after immunization by antigen-specific ELISA 
using hyper-immunized C3H/HeJ mice serum as a standard. C3H/HeJ mice were intravenously 
given 0.1 mg of DNP-KLH and implanted with hIL-6-loaded micro-osmotic pumps at 8 weeks of 
age, and anti-mIL6R mAbs were injected subcutaneously 1 day after immunization (n=5). Data are 
presented as the mean ( SD). 
Figure 1-3. (a) Concentration of IgG1 in IL-6 tgm. Serum IgG1 levels were determined by mouse 
IgG1-specific ELISA using mouse myeloma protein as a standard. (b) Changes of serum hIL-6 
levels in IL-6 tgm. Levels of hIL-6 were determined by hIL-6-specific ELISA. Data are presented as 
mean ( SE). n=7 for KH5-treated IL-6 tgm and n=6 for MR16-1-treated IL-6 tgm. (closed circle) 
KH5-treated IL-6 tgm: (open circle) MR16-1-treated IL-6 tgm. 
Figure 1-4. Plasmacytosis in IL-6 tgm. 
(a) Spleen weight of IL-6 tgm. Spleen weight was remarkably increased in IL-6 tgm treated with 
KH5. There were no significant differences in the MR16-1-treated IL-6 tgm or either littermate 
group. (b) Photomicrograph of spleen. Extensive proliferation of plasma cells in spleen was 
observed in IL-6 tgm treated with KH5, but not in IL-6 tgm treated with MR16-1. Original 
magnification 200. 
Figure 1-5. Changes of peripheral platelet counts (a), white blood cell counts (b), red blood cell 
counts (c), and hemoglobin levels (d) in IL-6 tgm. Hematological evaluations were performed on an 
automated micro-cell counter (Sysmex® F-800). Data are presented as the mean ( SE): (closed 
circle) KH5-treated IL-6 tgm: (open circle) MR16-1-treated IL-6 tgm: (closed square) KH5-treated 
littermates: (open square) MR16-1-treated littermates. 
Table 1-1. Blood chemical parameters in MR16-1-treated IL-6 tgm at 18 weeks of age 
-test; *P<0.05 (KH5-treated 
IL-6 tgm vs MR16-1-treated IL-6 tgm). 
Chapter 2: 
Evaluation of the anti-HCV activity of a newly identified SPT inhibitor, NA808, in 
vitro
1. Background and Aims 
As described in the Introduction, the current treatment regimen for HCV infection is a 
combination therapy of PEG-IFN with RBV; however, this therapy has limited efficacy and is not 
well tolerated in many patients due to its systemic side-effect profile, even when combined with 
recently approved NS3/4 protease inhibitors [7, 20]. Therefore, the ultimate goal of developing a 
therapy for chronic hepatitis C is likely to combine HCV enzyme-targeting agents, without using 
IFN or RBV. Currently, combination therapies of DAAs, such as NS3/4 serine protease inhibitors, 
NS5B RNA-dependent RNA polymerase inhibitors, and NS5A inhibitors, are being tested in clinical 
trials; however, the emergence of resistance mutations limits the efficacy of these therapies [26, 38]. 
In addition, the antiviral activity of DAAs is reduced in certain HCV genotypes [9]. Additional 
antiviral agents with high barriers to resistance and potent antiviral activity against a wide variety of 
HCV genotypes are necessary to establish robust and effective antiviral combination therapy without 
the use of IFN or RBV. 
The infection and replication process of HCV uses not only HCV proteins, but also several 
known and unknown host protein factors. Drugs that target host protein factors could provide 
therapies against HCV with a high barrier to resistance and with efficacy against a wide spectrum of 
HCV genotypes. I have identified a novel class of SPT inhibitors that inhibit HCV replication by 
disrupting host cell lipid rafts, which act as a scaffold for HCV replication [27]. Based on the 
mechanism of host enzyme-targeted viral inhibition, the newly identified SPT inhibitor, NA808, is 
hypothesized to have potential for its high barrier to resistance and for antiviral activity across 
different HCV genotypes. In this chapter, I describe the in vitro characteristics of NA808 to estimate 
its potential for further investigation as an anti-HCV drug candidate. 
2. Materials and Methods 
Compounds 
NA808 and telaprevir were synthesized by Chugai Pharmaceutical Co., Ltd. (Tokyo, 
Japan). 
Inhibition assay of replication in HuH7 cells harboring HCV subgenomic replicon cells 
The HCV subgenomic replicon cell FLR3-1 [27] (genotype 1b, Con-1) or R6 FLR-N [36] 
(genotype 1b, HCV-N) was seeded in 96-well tissue culture plates containing GlutaMax-I 
(DMEM-GlutaMax-I; Invitrogen, Carlsbad, CA, USA) with 5% FBS. After overnight incubation at 
37°C (5% CO2), serial dilutions of the reagents were added to the growth medium. Luciferase 
activity was determined after 72 h with a Bright-Glo luciferase assay kit (Promega, Madison, WI, 
USA). The viability of the replicon cells was determined using a cell counting kit (Dojindo, 
Anti-HCV assay of NA808 in HCVcc (JFH-1/K4 cells) 
Cured K4 (HuH7-K4) cells that continuously produce HCV viral particles (JFH-1/K4) 
were maintained in DMEM containing 10% fetal calf serum. JFH-1/K4 cells were seeded onto 
24-well tissue culture plates in DMEM supplemented with 10% fetal calf serum, and cultivated 
overnight at 37°C (5% CO2). Several concentrations of NA808 were added to the growth medium. 
After 72 hrs incubation, total RNA was extracted from the cells by the acid guanidinium 
thiocyanate-phenol-chloroform extraction method. HCV RNA was quantified by real-time PCR, as 
described previously [31].
Development of drug-resistant mutations in HCV subgenomic replicon cells 
The HCV subgenomic replicon cell line R6 FLR-N [36] (genotype 1b, HCV-N) was 
cultured with GlutaMax-I (DMEM GlutaMax-I; Invitrogen, Carlsbad, CA) containing 10% fetal 
bovine serum in the presence of 0.5 mg/mL G418 and 48 to 72 nM NA808 or 1.8 to 2.7 M 
telaprevir at a concentration of 4 to 6 times the 50% inhibitory concentration (IC50) value for 14 
passages. For the replicon assay, cells were seeded in 96-well tissue culture plates, and a 3-fold 
gradual dilution of NA808 or telaprevir in GlutaMax-I supplemented with 5% fetal bovine serum 
was added. Serial dilutions of both compounds were prepared from the stock solutions dissolved in 
dimethyl sulfoxide at a concentration of 1 mM for NA808 and 50 mM for telaprevir. Luciferase 
activity was determined with a Steady-Glo luciferase assay kit (Promega, Madison, WI). 
Deep sequencing of HCV genomes from genotype 1b replicon cells 
Deep sequencing of the HCV coding sequences was performed using the GS Junior 
System (Roche Diagnostics, Mannheim, Germany), according to the 
First, the acid guanidinium thiocyanate-phenol-chloroform extraction method was used to extract 
total RNA from the R6 FLR-N replicon cells after 14 passages with telaprevir or NA808 at a 
concentration of 6 times the IC50 value. Complementary DNA (cDNA) was then synthesized from 
the total RNA with random primers using Superscript III Reverse Transcriptase (Invitrogen, Life 
Technologies, Carlsbad, CA). The sequence of nucleotides 3429 to 9727 of the HCV genotype 1b 
replicon (R6NRz) genome, which includes all of the HCV protein coding sequence, was divided into 
several segments of 1.5 to 3 kb with overlapping regions. Four segments of the genotype 1b replicon 
genome were amplified from the cDNA by polymerase chain reaction (PCR) with specific primers 
(Table 2-1) using PrimeSTAR GXL DNA Polymerase (TaKaRa Bio, Shiga, Japan). The amplified 
segments of HCV cDNA were purified from 1% agarose gels using a MinElute Gel Extraction Kit 
(Qiagen, Valencia, CA) and quantified by measuring absorbance at 260 nm with a NanoDrop 1000 
Spectrophotometer (Thermo Scientific, Wilmington, DE). The cDNA segments covering the coding 
sequence of HCV were then pooled together at approximately equimolar ratios. The Covaris S220 
system (Covaris, Woburn, MA) was used to shear 500 ng of the pooled cDNA into 700- to 800-bp 
fragments. The sheared cDNA fragments were purified with the MinElute PCR Purification Kit 
(Qiagen), ligated with RL MID adaptors (Roche Diagnostics) to prepare the multiple cDNA libraries, 
and further purified with Agencourt AMPure XP beads (Beckman Coulter, Brea, CA). The quality 
and quantity of the libraries were assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, CA) and the KAPA Library Quantification Kit (Nippon Genetics, Tokyo, Japan), 
respectively. The libraries were then subjected to emulsion PCR, and enriched DNA beads 
(approximately 10% recovery) were loaded onto a picotiter plate and pyrosequenced with a GS 
Junior sequencer using titanium chemistry (Roche Diagnostics). Several libraries derived from the 
HCV genomes generated by different treatments were sequenced in a single GS Junior run. The data 
obtained were analyzed by the GS Reference Mapper software (Roche Diagnostics) to identify 
resistant mutations. 
SPT assay 
Crude extracts of the HCV subgenomic replicon cell line FLR3-1 [27] (genotype 1b, 
Con-1) were used as a source of SPT in this assay. Briefly, FLR3-1 cells were suspended in HSS 
buffer (10 mM HEPES-KOH, 25 mM sucrose, and 0.1% sucrose monolaurate) containing 1/100 
volume of protease inhibitor cocktail (Sigma, St Louis, MO) and sonicated 10 times with short 
pulses. After centrifugation at 10,000 rpm for 10 minutes, the supernatant was stored at -80°C until 
use. Crude extract of FLR3-1 cells was added to 0.015 mL of a reaction mixture containing 200 mM 
HEPES buffer (pH 8.0), 5 mM EDTA, 10 mM dithiothreitol, 0.05 mM pyridoxal 5-phosphate, 0.05 
mM palmitoyl-CoA, and 0.06 mM L-[14C]serine in the presence of NA808. After a 15-minute 
incubation at 37°C, 0.3 mL chloroform/methanol (1:2, v/v), 0.1 mL phosphate-buffered saline, and 
0.1 mL chloroform were added and mixed well. The extracts were spotted on TLC plates and 
chromatographed. Radioactive spots were evaluated using a Bio-imager. 
Statistical analysis 
Statistical analysis was performed using the Student t test. A P value <.05 was considered 
statistically significant. 
3. Results 
In vitro characteristics of NA808 
NA808 (Figure 2-1A), a derivative of NA255 isolated from fungal metabolites of 
Fusarium incarnatum F1476, demonstrated potent antiviral activity in HCV genotype 1b replicon 
cells with no apparent cellular toxicity under the assay conditions (Figure 2-2A) and decreased HCV 
propagation in genotype 2a HCVcc-producing cells (Figure 2-2C). NA255 is a selective inhibitor of 
SPT that inhibits HCV replication by suppressing the biosynthesis of sphingolipids that are required 
for HCV replication in replicon cells [27]. NA808 also inhibited the de novo synthesis of 
sphingolipids (Figure 2-2B). According to the Lineweaver-Burk plot of SPT inhibition in a replicon 
cell lysate, NA808 exhibited a noncompetitive inhibition pattern (Figure 2-1B). These findings 
suggest that NA808 inhibits HCV replication activity by preventing sphingolipid biosynthesis by a 
mechanism that inhibits SPT noncompetitively. 
NA808 shows a high barrier to resistance in vitro
To evaluate the potential development of resistance to NA808, replicon cells (R6 FLR-N) 
were cultured in the presence of both G418 and NA808 at a concentration of 4 to 6 times the IC50 for 
14 passages. Obvious changes in sensitivity to NA808 were not observed in these continuously 
treated replicon cells (Figure 2-2D), and the IC50 values were 18.9 nM (no treatment), 14.3 nM 
(treatment with 4 times the IC50), and 19.8 nM (treatment with 6 times the IC50). In contrast, there 
was a 5- to 17-fold increase of the IC50 values for telaprevir, an NS3/4 serine protease inhibitor, in 
replicon cells treated with 4 to 6 times the IC50 of telaprevir for the same duration (Table 2-2). The 
coding sequences of NS3 to NS5B from the replicon system after 14 passages with telaprevir or 
NA808 were determined by using deep sequencing. The sequences obtained at the 14th passage with 
telaprevir contained 3 known protease inhibitor resistance mutations (V36A, T54V, and A156T) [10] 
and NS5 region (Q181H, P223S, and S417P) (Table 2-3), suggesting that the increase in IC50 with 
telaprevir was accompanied by a shift in viral sequence. In contrast, no significant mutations were 
found in the 14th passage with NA808. Continuously treated replicon cells developed resistance to 
telaprevir, but not to NA808. 
4. Discussion 
In these experiments, the anti-HCV activity of NA808, a novel host SPT inhibitor, was 
evaluated in vitro. The HCV replication in HCV genotype 1b subgenomic replicon cell lines, 
FLR3-1 and R6 FLR-N, were suppressed by NA808 in a dose-dependent manner with no cell 
toxicity (Fig. 2-2A). In addition, NA808 decreased HCV RNA in genotype 2a HCVcc producing 
cells in a dose-dependent manner (Fig. 2-2C). These findings indicate that NA808 suppresses both 
the genotype 1b HCV-RNA replication and genotype 2a HCV propagation in vitro. 
The inhibitory activity of NA808 is attributed to its inhibition of the cellular enzyme SPT, 
which is necessary for viral replication. The mode of action of NA255, a lead compound of NA808, 
is to disrupt the scaffold where the HCV replication complex forms on host cellular lipid rafts [27]. 
NA808 potently inhibits the de novo biosynthesis of cellular sphingolipids, such as ceramide and 
sphingomyelin, in a dose-dependent manner (Figure 2-2B). NA808 also influences sphingolipid 
metabolism in host cells, and the metabolism of sphingomyelin, a type of sphingolipid, plays a 
multifaceted role in the HCV life cycle [12]. Additionally, altering the sphingolipid metabolism 
contributes to virion maturation and infectivity in the JFH-1 culture system [1]. These results suggest 
that NA808 affects many phases of the life cycle, including entry, replication, and maturation. 
The expected higher barrier of NA808 to developing resistant clones on the basis of its 
host-targeted unique mode of action is well confirmed. Obvious changes in drug sensitivity to 
NA808 are not observed in replicon cells treated continuously with NA808 (Table 2-2). 
Deep-sequencing analysis also showed no evidence for the development of NA808 resistance after 
14 passages in HCV replicon cells, while telaprevir treatment resulted in the selection of known 
protease resistance mutations (V36A, T54V, and A156T) (Table 2-3). 
These in vitro findings suggest that NA808 has potent anti-HCV activity across the HCV 
genotypes with a high barrier to developing resistance. 
Figure 2-1. Characteristics of NA808.
(A) Chemical structures of the compounds used in this study. (B) Scheme of de novo sphingolipid 
biosynthesis and Lineweaver-Burk plot of SPT assay results. Crude extract of FLR3-1 cells was 
incubated with L-[14C]serine in the presence of NA808. After incubation at 37°C, the extracts were 
spotted on TLC plates and chromatographed. 3-Ketodihydrosphingosine (3-KDS) generated from a 
bacterial SPT reaction is shown as a positive control marker. 
Figure 2-2. In vitro activities of NA808 
(A) Luciferase activity (circles) and cell viability (triangles) of FLR3-1 or R6 FLR-N subgenomic 
replicon cell lines in the presence of NA808. The data represent the mean values and the bars 
indicate the standard deviation (S.D.) of triplicate determinations. (B) Inhibition of de novo 
sphingolipid synthesis by NA808. The replicon cells were cultured with NA808 for 48 h and then 
labeled with [14C]serine for 18 h, and the newly synthesized lipids were analyzed by thin-layer 
chromatography (TLC). Cer, ceramide; SM, sphingomyelin; PE, phosphatidylethanolamine; PS, 
phosphatidylserine. (C) Cellular HCV-RNA levels (closed circles) and cell viability (open circles) of 
HCVcc-producing cells, named JFH-1/K4 cells, in the presence of NA808. (D) Activity on replicon 
cells cultured with NA808. Drug-resistant HCV replicons were selected in the presence of G418 and 
NA808 at a concentration of 4 to 6 times the IC50. Changes in drug sensitivity were examined after 
the 14th passage. The data represent the mean values and the bars indicate the standard deviation 
(S.D.) of triplicate determinations. 
D
Table 2-1. PCR primers used for deep sequencing of HCV genotype 1b from 
replicon cells 
 Primer Sequence 
R6 FLR-N replicon 
Segment 1  
Segment 2  
Segment 3  

















Data are indicated as the mean  S.D. 
Table 2-2. Changes in sensitivity to drug of HCV replicon cells after the 14th
passage in the presence of NA808 or telaprevir 
Drug No treatment IC50 4 IC50 6 
NA808 (nM) 18.9  2.82 14.3  5.52 19.8  7.86 
Telaprevir ( M) 0.39  0.022 2.14  0.019 6.48  1.30 
Data are indicated as the mean  S.D. 
Table 2-3. Summary of mutation frequency detected using deep sequencing for 
NA808- or telaprevir-treated replicon cells 
Drug Treatment Mutation Region Frequency (%) 
Telaprevir IC50 6, 14 passages V36A NS3 18.1 
  T54V NS3 26.9 
  A156T NS3 12.9 
  Q181H NS5A 25.2 
  P223S NS5A 23.3 
  S417P NS5A 15.8 
NA808 IC50 6, 14 passages not detected   
Nucleotide sequences based on deep sequencing of the NS3 to NS5B region from 
NA808- or telaprevir-treated replicon cells are compared to untreated controls, and 
amino acid mutations are shown.
Chapter 3: 
Evaluation of anti-HCV activity of NA808 in humanized liver chimeric mice 
infected with HCV 
1. Background and Aims 
In Chapter 2, I describe in vitro anti-HCV activity of NA808, which has potent anti-HCV 
activity on HCV-RNA replication in genotype 1b HCV subgenomic replicon cells and on HCV 
propagation in genotype 2a HCVcc with no evidence of developing resistance clones. These findings 
suggested that NA808 has potent anti-HCV activity across the HCV genotypes with a high barrier to 
developing resistance. Next, these beneficial profiles of NA808 as a novel drug candidate for 
anti-HCV treatment are confirmed in vivo to estimate its therapeutic potential in clinical practice. 
Preclinical research on HCV replication has been limited by a lack of appropriate infection 
models. The chimpanzee is known as the only animal species to permit HCV infection; however, the 
experimental use of chimpanzees is difficult because of ethical problems. To overcome this problem, 
Mercer et al. developed a chimeric SCID mouse carrying the albumin promoter controlled transgene 
that activates urokinase plasminogen and containing primary human hepatocytes in which infection 
and replication of intact HCV occurs [22]. Mercer s humanized liver chimeric mouse model was 
improved by Tateno et al. to have a higher substitution rate of human hepatocytes [33]. The use of 
this humanized liver chimeric mouse model is considered to bridge the gap between the replicon 
system and human liver and is suitable for evaluating the anti-HCV activity of NA808.  
Here, the therapeutic potential of NA808 as an anti-HCV agent is assessed using 
HCV-infected humanized liver chimeric mice, in terms of efficacy across HCV genotypes, 
synergistic effects with other antiviral agents, and the potential development of resistance. 
2. Materials and Methods 
Compounds 
NA808 and telaprevir were the same as in Chapter 2. PEG-IFN was purchased from 
Chugai Pharmaceutical Co., Ltd. Non-nucleoside polymerase inhibitor, HCV-796, and nucleoside 
polymerase inhibitor, RO-9187 [16], were synthesized by F. Hoffmann-La Roche Ltd. (Basel, 
Switzerland). 
Infection of HCV genotypes 1a, 1b, 2a, 3a, and 4a in humanized liver chimeric mice 
Chimeric mice were purchased from PhoenixBio Co., Ltd. (Hiroshima, Japan). The mice 
were generated by transplanting human primary hepatocytes into SCID mice carrying the urokinase 
plasminogen activator transgene controlled by an albumin promoter ( uPA/SCID). HCG9 (genotype 
1a, GenBank accession number AB520610), HCR6 (genotype 1b, AY045702), HCR24 (genotype 2a, 
AY746460), HCV-TYMM (genotype 3a, AB792683), and HCVgenotype4a/KM (genotype 4a, 
AB795432) were intravenously injected into the chimeric mice with humanized liver at 104 (for 
HCR6, HCR24, HCV-TYMM, and HCVgenotype4a/KM) or 106 (for HCR6 and HCG9) 
copies/mouse. After 4 weeks, the HCV RNA levels in the mice sera had reached approximately 108
copies/mL for HCG9 and HCV-TYMM and approximately 107 copies/mL for HCR6, HCR24, and 
HCVgenotype4a/KM. The protocols for animal experiments were approved by ethics committee at 
my institution. The animals received humane care according to National Institutes of Health 
guidelines. Patients gave written informed consent before blood or tissue samples were collected. 
Administration of NA808 and/or PEG-IFN, telaprevir, HCV-796, RO-9187 into HCV-infected 
humanized liver chimeric mice 
Treatment was started 12 weeks after HCV inoculation and continued for 14 days. Each 
treatment group contained at least 3 animals. NA808, PEG-IFN, RO-9187, HCV-796, and telaprevir 
were administered alone or in combination to chimeric mice infected with HCV genotype 1a 
(HCG9), genotype 1b (HCR6), genotype 2a (HCR24), genotype 3a (HCV-TYMM), or genotype 4a 
(HCVgenotype4a/KM). Blood samples and liver samples were collected according to the protocols 
shown in Table 3-1. All DAAs were used at suboptimal doses to demonstrate the synergy when 
administered in combination therapy. 
Quantification of HCV RNA by real-time reverse transcription PCR 
Total RNA was purified from 1 L chimeric mouse serum using SepaGene RV-R (Sanko 
Junyaku Co., Ltd., Tokyo, Japan) and total RNA was prepared from liver tissue by the acid 
guanidinium thiocyanate-phenol-chloroform extraction method. HCV RNA was quantified by 
quantitative real-time PCR using techniques reported previously [31]. This technique has a lower 
limit of detection of approximately 4000 copies/mL for serum. Therefore, all samples in which HCV 
RNA was undetectable were assigned this minimum value. 
Deep sequencing of HCV genomes from genotype 1a-infected chimeric mice 
The acid guanidinium thiocyanate-phenol-chloroform extraction method was used to 
extract total RNA from the liver tissue of HCV-infected chimeric mice that were treated with or 
without NA808 for 14 days. The sequence of nucleotides 325 to 9381 of the HCV genotype 1a 
(HCG9) genome, including all of the HCV protein coding sequence, was divided into several 
segments of 1.5 to 3 kb with overlapping regions. Seven segments of the genotype 1a (HCG9) 
genome were amplified from the cDNA by nested PCR with the indicated primers (Table 3-2). Other 
procedures were the same as Chapter 2. 
Statistical Analysis 
Statistical analysis was performed using the Student t test. A P value <.05 was considered 
statistically significant. 
3. Results 
Anti-HCV activity of NA808 in humanized liver chimeric mice infected with HCV 
To evaluate the anti-HCV effect of NA808 in vivo, humanized liver chimeric mice infected 
with HCV genotype 1a (HCG9) or 1b (HCR6) were used. The mice were transgenic uPA/SCID mice 
with reconstituted human livers; this mouse model supports long-term HCV infections at clinically 
relevant titers [14]. NA808 was administered via intravenous injection according to the schedule 
shown in Table 3-1. In mice infected with HCV genotype 1a, NA808 (5 mg/kg/d) led to a rapid 
decrease in serum HCV-RNA (approximately a 2-log decrease within 14 days) (Figure 3-1A). A 
similar decrease in serum HCV-RNA occurred in mice infected with HCV genotype 1b that were 
treated with NA808 (5 mg/kg/d) (Figure 3-1C). NA808 also reduced hepatic HCV-RNA at the end of 
the treatment period in a dose-dependent manner (Figure 3-1B and D). These results indicate that 
NA808 has a robust antiviral effect in humanized liver chimeric mice infected with HCV genotype 
1a or 1b. The most effective dose was 5 mg/kg/d in both genotype 1a- and genotype 1b-infected 
mice; therefore, this dose was used for further experiments. 
To address whether NA808 had antiviral activity across HCV genotypes, chimeric mice 
infected with various strains of HCV were treated with 5 mg/kg of NA808 for 14 days, and then the 
HCV-RNA levels in sera were evaluated. Inoculation with several HCV strains, HCG9 (genotype 1a), 
HCR6 (1b), HCR24 (2a), HCV-TYMM (3a), and HCVgenotype4a/KM(4a), resulted in HCV titers in 
the sera of mice of approximately 108 (HCG9 and HCVTYMM) and 107 (HCR6, HCR24, and 
HCVgenotype4a/KM) copies/mL, respectively (Figure 3-2). At 14 days after administration, NA808 
treatment resulted in approximately 1- to 3-log reductions of serum HCV-RNA in each 
genotype-infected group (Figure 3-1E). Human serum albumin levels were not changed during the 
administration period, suggesting that the anti-HCV activity of NA808 against several genotypes 
occurred without any overt toxicity. NA808 was effective and well tolerated in chimeric mice with 
humanized liver infected with several genotypes of HCV. 
Deep sequencing of HCV genotype 1a from humanized liver chimeric mice 
Full-genome sequence analysis of HCV in the humanized liver chimeric mouse model 
after 14 days of NA808 administration was performed. The viral RNA was extracted from liver 
tissues of humanized liver mice, amplified using the primer sets shown in Table 3-2, and sequenced 
with the Roche/454 GS Junior sequencer using titanium chemistry. A total of 43,911 and 68,272 
sequence reads for HCV genomes were obtained from untreated mice and from NA808-treated mice, 
respectively. The sequences were determined by comparing them with the HCG9 reference sequence 
(GenBank accession number AB520610), and, as a result, the viral sequences from NA808-treated 
mice were identical to those from untreated mice. 
Synergistic effects of NA808 with PEG-IFN or DAAs in chimeric mice infected with HCV 
The in vivo synergistic effects of NA808 combined with PEG-IFN on HCV replication 
were investigated using humanized liver chimeric mice infected with HCV genotypes 1a, 2a, and 4a. 
For 14 days, NA808 was administered intravenously with or without a subcutaneous injection of 
PEG-IFN. In mice infected with HCV genotype 1a, the combination therapy of NA808 with 
PEG-IFN led to a rapid decrease in serum HCV-RNA of about 4 log within 10 days (Figure 3-3A), 
and monotherapy with NA808 or PEG-IFN achieved about a 2-log or 1-log decrease, respectively 
(Figure 3-4A). The levels of serum HCV-RNA were also significantly reduced in genotype 2a- and 
4a-infected chimeric mice that received the combination treatment (Figure 3-3A). Although 
sensitivity to the combination treatment varied according to HCV genotype (1a, 2a, or 4a), the serum 
HCV-RNA level eventually fell below the level of detection in all mice treated with the combination 
of NA808 and PEG-IFN (Figure 3-3A); this result was consistent with the significant reductions in 
hepatic HCV-RNA levels at day 14 (Figure 3-3B). To determine if NA808 has a synergistic effect 
with DAAs, combination treatment with NS5B nucleoside inhibitor, RO-9187 [16], NS5B 
polymerase non-nucleoside inhibitor, HCV-796, or NS3/4A protease inhibitor, telaprevir, in HCV 
genotype 1a- or 1b-infected chimeric mice was examined. Oral administration of once-daily 1000 
mg/kg RO-9187, 100 mg/kg HCV-796, or 400 mg/kg telaprevir had only very limited or no apparent
effect on serum HCV-RNA levels during the 14 days of treatment (Figure 3-4B, C, and D). However, 
the combination therapy of NA808 with RO-9187, HCV-796, or telaprevir led to a decrease in serum 
HCV-RNA levels of about 2.6 log, 3.5 log, and 2.5 log, respectively, within 14 days (Figure 3-4B, C, 
and D); these reductions were all in excess of the viral load reduction achieved by treatment with 
NA808 (5 mg/kg) alone. These data suggest that NA808 has synergistic antiviral effects with HCV 
enzyme-targeted drugs in vivo, regardless of the targeted enzyme. The combination therapy of 
NA808 with telaprevir and HCV-796 resulted in up to 4.7-log reduction of serum HCV-RNA within 
14 days (Figure 3-4D). At the end of the treatment, hepatic HCV-RNA levels were also reduced, 
correlating with the reduction of serum HCV-RNA (Figure 3-4E). 
4. Discussion 
In Chapter 2, the potent in vitro anti-HCV activity of NA808 across several HCV 
genotypes with no evidence of developing resistance clones is described. Following these findings, 
in vivo anti-HCV activity of NA808 is evaluated in human primary hepatocytes transplanted into 
uPA/SCID mice to assess the therapeutic potential of NA808 in clinical practice as an anti-HCV 
agent. These humanized liver chimeric mice infected with HCV genotypes 1a, 1b, 2a, 3a, and 4a 
could support long-term HCV infections at clinically relevant titers, hence these mice are considered 
a suitable model in which to evaluate the anti-HCV activity of NA808. 
Based on the mechanism of action, NA808 could be anticipated to have antiviral activity 
against a wide variety of HCV genotypes and have a high barrier to developing resistance. These 
hypotheses are also confirmed in vivo; the humanized liver chimeric mice infected with HCV 
genotypes 1a, 1b, 2a, 3a, and 4a and treated with NA808 show significant reductions of serum 
HCV-RNA in each genotype-infected group (Figure 3-1E), and the full-genome sequences of HCV 
obtained from HCV-infected humanized liver chimeric mice treated with NA808 for 14 days show 
no evidence of selection of resistance mutations, which is consistent with the viral load kinetics 
(Figure 3-1A).  
To estimate the effects of NA808 in DAA combination therapy without the use of IFN or 
RBV, a combination treatment of NA808 with NS5B polymerase inhibitors and/or NS3/4A protease 
inhibitors was evaluated in chimeric mice with humanized liver infected with HCV. Both 
non-nucleoside inhibitors and nucleoside inhibitors of NS5B are currently being tested in clinical 
trials, and the most advanced protease inhibitors, such as telaprevir, are linear compounds that are 
currently on the market, while several macrocyclic compounds are being tested in clinical trials [9, 
18, 19, 29, 34]. Monotherapy with the non-nucleoside polymerase inhibitor, HCV-796, showed a 
reduction of less than 0.5 log in serum HCV RNA levels, while a combined treatment with NA808 
reduced the HCV titer by 1000-fold from the initial serum levels. This effect was higher than the 
effect of NA808 alone and higher than the totaled effects of NA808 and HCV-796 monotherapies, 
suggesting a synergistic antiviral efficacy. A similar effect was observed by combining NA808 with 
nucleoside polymerase inhibitor, RO-9187, as shown in Figure 3-4B. The maximum reductions in 
HCV RNA are mediated by triple combination treatment and the significant in vivo anti-HCV 
activity with combination treatment is also observed when NA808 is combined with PEG-IFN. 
These observations suggest that NA808 may have synergistic antiviral activity with various classes 
of anti-HCV agents, regardless of their inhibition mechanism, because of its unique mechanism of 
action that targets the host enzyme. NA808 influences sphingolipid metabolism in host cells, which 
contributes to many phases of the HCV life cycle [1, 12]. It seems that these diverse working points 
in the HCV life cycle along with the differentials of the target site could be a reason for the enhanced 
anti-HCV activity of combination treatment with NA808 and other anti-HCV agents. 
Host enzyme inhibition is sometimes associated with mechanism-related toxicity or side 
effects. Although more thorough analyses of toxicity with NA808 are warranted, it was 
well-tolerated in vivo at the efficacious dose used. Besides, NA808 did not affect host cell viability 
in vitro under the assay conditions described in Chapter 2 (Figure 2-2A). Homozygous knockout 
mice for sptlc1 and sptlc2, subunits of SPT, were embryonic lethal; however, heterozygous mice 
showed no phenotype [13], and the short term deficiency of sptlc2 in conditional knockout mice 
induced no severe phenotypes except necrotic lesions in gastrointestinal cells [24]. Thus, inhibiting 
SPT would not result in severe adverse events except during fetal life and in the case of complete 
systemic elimination. In addition, the potential systemic toxicity associated with SPT inhibition by 
NA808 may be limited by the highly selective distribution of NA808 to the liver [25]. 
Thus, NA808 mediates potent anti-HCV activity in a variety of genotypes with an 
apparently high barrier to resistance. Synergistic effects with PEG-IFN, HCV protease, and/or 
polymerase inhibitors are observed in humanized liver chimeric mice infected with HCV. These 
findings suggest that NA808 has potential as a novel host-targeted drug in the treatment of HCV 
infection. NA808 is considered a promising candidate for DAA combination treatment that does not 
use IFN or RBV and that prevents the development of drug resistance while effectively inhibiting a 
wide spectrum of HCV genotypes. 
Figure 3-1. Antiviral effects of NA808 in various HCV genotypes. 
(A, C) Time course of serum HCV-RNA levels in chimeric mice infected with HCV genotype 1a (A) 
or genotype 1b (C) treated with vehicle or several doses of NA808 (closed circles: 5 mg/kg/d; open 
circles: 3 mg/kg/d; closed triangles: 1.5 mg/kg/d; open triangles: vehicle). (B, D) HCVRNA levels in 
the livers of chimeric mice infected with HCV genotype 1a (B) or genotype 1b (D) at the end of 
treatment. Error bars = SD (*P < .05). (E) Time course of serum HCV-RNA levels in the sera of 
genotype 1a (closed circles), 1b (open circles), 2a (closed triangles), 3a (open triangle), and 4a 




Figure 3-2. Time-course studies in chimeric mice inoculated with human HCV-positive sera of 
several HCV genotypes 
HCV RNA levels in chimeric mouse serum after inoculation with HCV genotypes 1a (A), 1b (B), 2a 
(C), and 4a (D). Error bars indicate S.D. 
Figure 3-3. Antiviral effect of combination treatment of NA808 with PEG-IFN on HCV-infected 
chimeric mice.
(A) Time course of serum HCV-RNA levels in chimeric mice infected with genotype 1a, 2a, or 4a 
and treated with a combination of NA808 (5 mg/kg/d, intravenously) and PEG-IFN (30 g/kg/twice 
weekly, subcutaneously). HCV-RNA levels one day before administration are shown by black bars. 
(B) HCV-RNA levels in the liver 14 days after the initiation of combination therapy with NA808 and 
PEG-IFN. Error bars = SD. *P < .05; **P < .01. 
Figure 3-4. Combination treatment of NA808 with PEG-IFN or direct-acting antiviral agents 
exhibits robust anti-HCV activity in humanized liver chimeric mice.  
(A-D) Median change from baseline of serum HCVRNA over the 14-day monotherapy or 
combination therapy of NA808 (5 mg/kg/d, intravenously) with PEG-IFN (A: 30 g/kg/twice 
weekly, subcutaneously), RO-9187 (B: 1000 mg/kg/d, orally), HCV-796 (C: 100 mg/kg/d, orally), or 
telaprevir (400 mg/kg/d, orally) and/or HCV-796 (D). (E) HCV-RNA levels in livers of 
HCG9-infected chimeric mice at the end of each treatment. Error bars = SD. (*P < .05). 

Table 3-2. PCR primers used for deep sequencing of HCV genotype 1a from chimeric mice 
  Primer Sequence 
HCG9    
Segment 1 1st PCR HCG9-321-S17 -AGGTCTCGTAGACCGTG-
  HCG9-2434-R20 -TCCACGATGTTCTGGTGGAG-
 2nd PCR HCG9-325-S22 -CTCGTAGACCGTGCACCATGAG-
  HCG9-2012-R24 -TGAGTTCATCCAAGTGCAACCGAA-
Segment 2 1st PCR HCG9-1143-S16 -AGCGCCACCCTCTGCT-
  HCG9-3558-R21 -AGGTTGCCAGGAAGGTCTGGG-
 2nd PCR HCG9-1153-S20 -TCTGCTCGGCCCTCTATGTA-
  HCG9-3548-R19 -GAAGGTCTGGGCAGCAGTT-
Segment 3 1st PCR HCG9-2088-S20 -ACTGACTGTTTCCGCAAGCA-
  HCG9-4705-R20 -TTGCAGTCTATCACCGAGTC-
 2nd PCR HCG9-2156-S20 -CAGGTGCCTGGTCCACTATC-
  HCG9-4640-R19 -GACAACATCGCCACTGGTT-
Segment 4 1st PCR HCG9-3414-S19 -TTGCTGGCGCCCATCACGG-
  HCG9-5959-R20 -ACCTCACCGCTCATGATCTT-
 2nd PCR HCG9-3454-S19 -GCCTCCTGGGATGCATAAT-
  HCG9-5906-R20 -ATACCCTGCAAGGATGTCCA-
Segment 5 1st PCR HCG9-4536-S19 -AAGTGCGACGAGCTCGCTG-
  HCG9-7221-R19 -TGTAGTCCGGCCGTGCCCA-
 2nd PCR HCG9-4577-S20 -CAATGCCGTGGCTTACTACC-
  HCG9-7146-R20 -AGATCTCCCGTTCGTCCTCT-
Segment 6 1st PCR HCG9-5872-S19 -TGGGGAAGGTCCTCGTGGA-
  HCG9-8886-R20 -AGTGGGGCAGCAGTATCATT-
 2nd PCR HCG9-5878-S20 -AGGTCCTCGTGGACATCCTT-
  HCG9-8832-R20 -TGCCTAGCCAGGAATTGACT-
Segment 7 1st PCR HCG9-7852-S21 -CCGTAGAGGAAGCTTGCAGCC-
  HCG9-9404-R20 -AAGAGGCCGGAGTGTTTACC-
 2nd PCR HCG9-7962-S20 -TCCGTGTGGAAAGACCTTCT-
  HCG9-9381-R26 -ACCTTCATCGGTTGGGGAGGAGGTAG-
Conclusion 
In this study, I attempt to estimate the clinical performance of two drug candidates, an 
anti-IL-6R mAb for Castleman s disease and a SPT inhibitor for chronic hepatitis C, from preclinical 
evaluations. Although the preclinical profiles of drug candidates must be clarified to estimate their 
clinical potential, the applicability of preclinical research to the clinical profiles varies a great deal 
depending on the availability of suitable experimental models. It is considered difficult to estimate 
the clinical potential of these two drug candidates from preclinical research by standard techniques, 
because of species specificity and the lack of appropriate models.  
fever, anemia, and hypergammaglobulinemia, with an abnormal augmentation of IL-6 [37]. There 
were no suitable animal models to research Castleman s disease before IL-6 tgm were established. 
IL-6 tgm develop various disorders, including massive IgG1 plasmacytosis, mesangial proliferative 
glomerulonephritis, thrombocytosis, leukocytosis, anemia, and muscle atrophy with dysregulated 
IL-6 overproduction [15]. Most of these disorders . 
These findings suggest that IL-6 tgm is a suitable Castleman s disease model with matched 
pathogenesis and identical symptoms. 
It has been reported that blocking the IL-6 signal transduction by administering anti-IL-6 
or -IL-6R mAb to neutralize the IL-6 function results in beneficial effects in patients with 
 [5, 23]. As described in Chapter 1, I attempt to confirm the clinical benefits of 
IL-6 signal-blocking agents in preclinical research by administering anti-IL-6R mAb to IL-6 tgm. 
For this purpose, I prepared a rat anti-mouse IL-6R mAb to block the IL-6 signal in IL-6 tgm, since 
the anti-IL-6R mAb used in clinic is specific to humans. Administering rat anti-mouse IL-6R mAb 
with potent IL-6 signal-neutralizing activity completely eliminates the various disorders in IL-6 tgm 
that are identical to those in Castleman s disease. These findings are consistent with the previous 
report by Nishimoto et al. that indicates that administering anti-human IL-6R mAb improves various 
symptoms, such as anemia, hypoalbuminemia, hypergammaglobulinemia, and lymphadenopathy, in 
patients with Castleman s disease [23]. This means I could confirm the effects of IL-6 
signal-blocking agents in patients with Castleman s disease in a preclinical experiment. These 
findings suggest that even in the difficult-to-estimate diseases the clinical performance of drug 
candidates could be estimated in preclinical evaluation when using appropriate models that are 
clinically relevant. 
In Chapters 2 and 3, I describe the preclinical evaluation of NA808, a novel identified SPT 
inhibitor, as an anti-HCV agent. Development of new anti-HCV drugs has been significantly 
impeded by the lack of suitable infectious models both in vitro and in vivo. This obstacle has been 
partially overcome by the development of replicon cells, which can be used for evaluating the in 
vitro anti-HCV effect of drug candidates. However, this system could reflect only RNA replication in 
the HCV life-cycle and has an adaptive mutation into the replicon genome that permits particularly 
efficient replication in cultured hepatoma cell lines [4]. Therefore, evaluating HCV drugs by the 
replicon system alone is considered insufficient for applying the data to patients. The only animal 
species readily infected with HCV is the chimpanzee, which is difficult to use because of critical 
ethical problems, the necessity of labor-intensive work, and the high cost. The chimeric mouse with 
human hepatocytes has recently been developed as a practical small animal model that can be 
infected with HCV [22]. As described in Chapter 3, I use improved humanized liver chimeric mice 
as developed by Tateno et al, which have a higher substitution rate of human hepatocytes than the 
initially developed chimeric mice by Mercer et al [33]. These mice infected with HCV genotypes 1a, 
1b, 2a, 3a, and 4a could support long-term HCV infections at clinically relevant titers; hence, these 
mice are considered to bridge the gap between the replicon system and naive HCV replication in the 
human liver and to be a suitable model for evaluating the anti-HCV activity of NA808. 
The IFN-based current standard therapies for HCV infection have limited efficacy and 
significant adverse effects even when combined with the recently approved NS3/4 protease 
inhibitors [7, 11, 17, 20,28]. Combination therapies of HCV enzyme-targeting agents without the use 
of IFN are being tested in clinical trials; however, the emergence of resistance mutations limits the 
efficacy of these therapies [26, 28]. In addition, the antiviral activity of these agents is reduced for 
certain HCV genotypes [9]. Therefore, antiviral agents with high barriers to resistance and potent 
antiviral activity against a wide variety of HCV genotypes are considered necessary to establish 
robust and effective anti-HCV therapies. The infection and replication process of HCV can use not 
only HCV proteins but also several known and unknown host protein factors. Drugs that target host 
protein factors could provide therapies against HCV with a high barrier to resistance and efficacy 
against a wide spectrum of HCV genotypes. Based on the mechanism of host enzyme-targeted viral 
inhibition, NA808 is hypothesized to have potential for a high barrier to resistance and for antiviral 
activity across different HCV genotypes. These expected profiles of NA808 have been observed in 
replicon cells and well confirmed in humanized liver chimeric mice infected with HCV. Besides, 
NA808 indicates synergistic antiviral activity with various classes of anti-HCV agents in 
HCV-infected humanized liver chimeric mice, regardless of their inhibition mechanism. These 
findings strongly suggest that NA808 is considered a promising drug candidate in the treatment of 
HCV infection with a high barrier to developing drug resistance, activity against a wide spectrum of 
HCV genotypes, and synergy with other anti-HCV drugs. 
In conclusion, the results in the Castleman s disease model treated with anti-IL-6R mAb 
suggest that preclinical assessment might be capable of predicting the clinical performance, when 
using appropriate models with clinical relevance. In HCV-infected humanized liver chimeric mice, 
viral replication occurred in human hepatocytes, and long-term infection could be supported at a 
clinically relevant titer; hence, these mice are considered a suitable model with clinical relevance for 
evaluating anti-HCV drug candidates. Therefore, beneficial profiles of NA808 as an anti-HCV drug 
in HCV-infected humanized liver chimeric mice could reflect the drug s clinical potential and 
support the development of NA808 as a treatment for HCV infection or for use in combination with 
PEG-IFN or HCV polymerase or with protease inhibitors. 
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